节点文献

Ⅲ型慢性前列腺炎合并勃起功能障碍的中西医结合治疗临床观察

Effects of Huafenqinutang and vardenafil for treatment of chronic prostatitis/chronic pelvic pain syndrome with concomitant erectile dysfunction

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 林中方陈宝田曾抗兰海梅温炬

【Author】 LIN Zhong-fang 1, CHEN Bao-tian1, ZENG Kang2, LAN Hai-mei2, WUN Ju3 Department of Internal Medicine, School of Traditional Chinese Medicine1, Department of Dermatology, Nanfang Hospital2, Southern Medical University, Guangzhou 510515, China; 3Department of Dermatology, Second People’s Hospital of Guangdong Province, Guangzhou 510317, China

【机构】 南方医科大学中医药学院内科教研室南方医科大学南方医院皮肤科广东省第二人民医院皮肤科 广东广州510515广东广州510515广东广州510317

【摘要】 目的探讨花粉芪奴汤结合伐地那非治疗Ⅲ型慢性前列腺炎(CP/CPPS)合并勃起功能障碍(ED)的疗效。方法CP/CPPS合并ED患者138例,随机分为两组:治疗组70例,使用花粉芪奴汤4周后加用伐地那非治疗;对照组68例持续使用花粉芪奴汤8周。分别于第4和第8周末进行NIH-CPSI评分和ⅡEF-5评分观察疗效。结果4周末治疗组和对照组NIH-CPSI分别为13.1±4.7和13.3±4.5,较治疗前均显著下降(P<0.01),两组间比较差异无统计学意义(P>0.05),两组ⅡEF-5评分分别为14.1±3.3和14.3±5.0,较治疗前有所上升(P<0.01),但两组间比较差异无统计学意义(P>0.05)。8周后治疗组NIH-CPSI评分7.8±2.8、ⅡEF-5评分20.1±4.4与4周末比较差异均有统计学意义(P<0.01);对照组NIH-CPSI评分12.7±2.3、IIEF-5评分14.3±4.5、与4周末比较差异均无统计学意义(P>0.05);两组间NIH-CPSI与ⅡEF-5评分比较差异均有统计学意义(P<0.01),治疗组ⅡEF-5评分值与NIH-CPSI值呈负相关关系。结论对CP/CPPS合并ED患者在使用花粉芪奴汤加用伐地那非能有效治疗ED,同时使NIH-CPSI评分降低,促进CP/CPPS恢复。

【Abstract】 Objective To evaluate the effects of Huafenqinutang combined with vardenafil for the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) with erectile dysfunction. Methods One hundred and thirty-eight cases diagnosed as CP/CPPS with erectile dysfunction were randomized into trial group (70 cases) and control group (68 cases) for treatment with Huafenqinutang for 8 weeks, and in the former group, vardenaffil was added since the fifth weeks. All the cases were evaluated according to NIH-CPSI and ⅡEF-5 scores at 4 weeks and 8 weeks, respectively. Results At the end of the fourth weeks, NIH-CPSI score was 13.1±4.7 in the trial group and 13.3±4.5 in the control group, which were comparable between the two groups (P>0.05) but significantly decreased compared with the pre-treatment scores in both groups (P<0.01). ⅡEF-5 score was also similar between the two groups (14.1±3.3 vs 14.3±5.0, P>0.05) but significantly increased compared with the pre-treatment scores in both groups (P<0.01). At the end of the eighth week, NIH-CPSI score was 7.8±2.2 and ⅡEF-5 score 20.1±4.4 in the trial group, which were significantly different from those at the end of the fourth week (P<0.01). In the control group, NIH-CPSI score was 12.7±2.3 and ⅡEF-5 score 14.3±4.5 at the eighth week, similar to those at the end of the fourth week (P>0.05). There were significant differences in NIH-CPSI and ⅡEF-5 scores between the 2 groups (P<0.01), and the change of NIH-CPSI score was negatively correlated with IIEF-5 score in the trial group (r=-0.89, P<0.01). Conclusion For patients with CP/CPPS with erectile dysfunction, Huafenqinutang treatment in combination with vardenafil can effectively improve the erectile functions and decrease the NIH-CPSI score to favor the recovery from CP/CPPS.

  • 【文献出处】 南方医科大学学报 ,Journal of Southern Medical University , 编辑部邮箱 ,2007年04期
  • 【分类号】R697.3;R698.1
  • 【被引频次】5
  • 【下载频次】142
节点文献中: 

本文链接的文献网络图示:

本文的引文网络